PMX

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Retrieved on: 
Monday, May 2, 2022
Record, FDIC, New, Tax, Leg, Environment, PCQ, Loss, PNI, Risk, Mission statement, PDO, PCK, Government, Investment, Unitary state, News, Government agency, Income, Federal Reserve Board of Governors, Time, PMX, New York Stock Exchange, Delinquent, Sale, PNF, Calendar, NAV, PMF, Annual report, PZC, Contingent convertible bond, PML, Bank, Clos, PIMCO, Life insurance, Security (finance), Fund

There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Key Points: 
  • There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.
  • The tax treatment and characterization of a Funds distributions may varysignificantly from time to time because of the varied nature of the Fundsinvestments.
  • As with any stock, the price of a Funds common shares will fluctuate with market conditions and other factors.
  • PIMCO Investments LLC, 1633 Broadway, New York, NY 10019, is a company of PIMCO.

Publicis Health Media Announces Industry-Driving Solutions at the PHM HealthFront 2022

Retrieved on: 
Monday, May 2, 2022
Name, Ecosystem, Population, No, Publicis Healthcare Communications Group, Twitter, POC, Gaps, PHM, IHeartRadio, Physician, Liverpool Care Pathway for the Dying Patient, PMX, Patient, SOV, Athlete, The Game Changers, Narration, Medscape, Industry, Knowledge, Me, Leadership, Health, Human, Marketing, Digitas NewFront, Conference, HCPS, Solution, HCP, Curriculum, Technology, Heart, Publicis, Entertainment, Public relations, Online shopping

By launching new and innovative solutions, PHM endeavors to drive the health media marketplace forward: to be more impactful and more closely aligned with evolving consumer and marketplace behavior, while improving health experiences along people's unique health journeys.

Key Points: 
  • By launching new and innovative solutions, PHM endeavors to drive the health media marketplace forward: to be more impactful and more closely aligned with evolving consumer and marketplace behavior, while improving health experiences along people's unique health journeys.
  • To work with PHM, please contact [email protected]
    PHM is the leading health media agency in the US.
  • We are designed forand dedicated todelivering best-in-class solutions that connect people with meaningful health and wellness solutions every day.
  • At PHM, we sit squarely at the intersection of Publicis Health, the largest Healthcare Communications network in the world, and Publicis Media, the number one buyer of media in the US.

Spectral to Present at Investor Summit Group's Q2 In-person Conference on May 3rd in NYC

Retrieved on: 
Wednesday, April 27, 2022
Consumer, News, Communication services sector reshuffle, Real estate, Toronto Stock Exchange, SAMI, Patient, Sepsis, Renal replacement therapy, Conference, The Westin New York Grand Central Hotel, Company, EDT, Complimentary, PMX, U.S. FDA, Summit Group, TSX, Health Canada, Spectral, FDA, RRT, Risk, Federal Food, Drug, and Cosmetic Act, Septic shock, Medical device, Technology, Finance, Health care

The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

Key Points: 
  • The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q2 Investor Summit Group will take place in-person, featuring 65+ companies and over 300 investors comprising institutional investors, family offices, and high net worth investors.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.
  • The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Retrieved on: 
Friday, April 1, 2022
New York Stock Exchange, Risk, Mission statement, Loss, Environment, Delinquent, Federal Reserve Board of Governors, Time, New, PDO, Sale, Record, Investment, Tax, Government agency, Income, Unitary state, NAV, PCQ, Contingent convertible bond, PMF, Annual report, PIMCO, PNF, Government, Bank, PNI, Leg, PMX, Clos, PCK, PML, Calendar, PZC, News, FDIC, Life insurance, Security (finance), Fund

There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Key Points: 
  • There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.
  • The tax treatment and characterization of a Funds distributions may varysignificantly from time to time because of the varied nature of the Fundsinvestments.
  • As with any stock, the price of a Funds common shares will fluctuate with market conditions and other factors.
  • PIMCO Investments LLC, 1633 Broadway, New York, NY 10019, is a company of PIMCO.

Spectral Announces Fourth Quarter and Fiscal 2021 Results and Corporate Update

Retrieved on: 
Thursday, March 24, 2022
Risk, Dialysis, Toronto Stock Exchange, Forecasting, Pathology, Hospital, CEO, Privatization, Sepsis, Goal, GLOBE, SMTC Corporation, Recurrence, U.S. FDA, Marketing, Acute kidney injury, EDT, SAMI, Industry, Treasury, Health Canada, Septic shock, Intensive care unit, Clinical trial, Board, Mortality, CFO, Health, SOFA, COVID, FDA, Patient, Federal Food, Drug, and Cosmetic Act, Company, RRT, Renal replacement therapy, Leadership, Particle-size distribution, PMX, TSX, CRRT, H.I.G. Capital, COVID-19, News, Electronics, SMTC, Baxter International, Acquisition, Pharmaceutical industry, Medical device, Airline, Spectral, Nasdaq

Revenue for the three months ended December 31, 2021 was $517,000 compared to $535,000 for the same three month period last year.

Key Points: 
  • Revenue for the three months ended December 31, 2021 was $517,000 compared to $535,000 for the same three month period last year.
  • For the quarter ended December 31, 2021, the Company reported operating costs of $3,069,000 compared to $2,682,000 for the corresponding period in 2020.
  • Loss for the quarter ended December 31, 2021 was $2,552,000 ($0.010 per share) compared a loss of $2,147,000 ($0.009 per share) for the same quarter last year.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.

Spectral Medical Announces Appointment of Blair McInnis as CFO

Retrieved on: 
Monday, March 21, 2022
Company, Risk, Toronto Stock Exchange, RRT, Renal replacement therapy, Ernst, U.S. FDA, Federal Food, Drug, and Cosmetic Act, Growth, Patient, Compliance, PMX, Forecasting, EDT, CEO, Bachelor of Commerce, SAMI, TSX, Ernst & Young, Privatization, Sepsis, Acquisition, H.I.G. Capital, GLOBE, News, SMTC Corporation, SMTC, Electronics, Commerce, Certified Public Accountant, FDA, Telecommunication, Treasury, Health Canada, Septic shock, Pharmaceutical industry, Management, Medical device, Spectral, Nasdaq, Laurentian University

Mr. McInnis assumes the role of Chief Financial Officer from Chris Seto, who will continue as Chief Executive Officer of the Company.

Key Points: 
  • Mr. McInnis assumes the role of Chief Financial Officer from Chris Seto, who will continue as Chief Executive Officer of the Company.
  • During his tenure, he helped oversee the financial aspects of the acquisition and privatization of the Company by H.I.G.
  • Chris Seto, CEO of Spectral, commented, I am delighted to welcome Blair to the senior management team.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum.

Dialco Medical Announces Formation of Medical Advisory Board to Support the Continued Development of DIMI Device

Retrieved on: 
Wednesday, March 16, 2022
Health Canada, Toronto Stock Exchange, Sepsis, Harbor–UCLA Medical Center, Hospital, CMO, University, Renal replacement therapy, GLOBE, Clinical Journal of the American Society of Nephrology, Patient, University Health Network, News, Society, Partnership, FDA, Editing, CS, Risk, Federal Food, Drug, and Cosmetic Act, Dialysis, Washington University in St. Louis, Yale School of Medicine, Safety, Professor, Toronto General Hospital, EDT, PMX, FREEDOM, Hypertension, U.S. FDA, Company, RRT, CEO, Division, Health, TSX, SAMI, Toronto, MSN, MS, Septic shock, Pharmaceutical industry, Medical device, MD, Spectral, Nephrology, Medicine

TORONTO, March 16, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced that its wholly owned subsidiary, Dialco Medical Inc. (Dialco), has formed a Medical Advisory Board to support in guiding the DIMI usability trial and continued development of the DIMI device.

Key Points: 
  • TORONTO, March 16, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced that its wholly owned subsidiary, Dialco Medical Inc. (Dialco), has formed a Medical Advisory Board to support in guiding the DIMI usability trial and continued development of the DIMI device.
  • Fredric Finkelstein, MD, is Clinical Professor of Medicine at the Yale University Medical School, as well as a Nephrology Specialist and key proponent of patient-centered care.
  • Chris Seto, CEO of Spectral, commented, "The establishment of our Medical Advisory Board is an important resource as we prepare to commence our upcoming DIMI usability trial in 2022.
  • DIMI is an easy-to-use home hemodialysis machine, built on the same platform as the Companys SAMI device.

Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022

Retrieved on: 
Friday, March 4, 2022
Lipopolysaccharide, Risk, U.S. FDA, TSX, Patient, Health Canada, PMX, Critical care, Research, Hemofiltration, News, Renal replacement therapy, Hilton San Diego Bayfront, FDA, Acute kidney injury, Exhibition, RRT, Pathogen, Septic shock, Late, Conference, CRRT, AKI, SAMI, Learning, EDT, Toronto Stock Exchange, Stony Brook University, Sepsis, Nursing, Technology, Kidney, International Conference on Information Systems Security and Privacy, Spectral, GLOBE, Federal Food, Drug, and Cosmetic Act, Pharmaceutical industry, Medical device

Invited lectures, workshops, dedicated sessions for nursing, poster sessions and panel discussions are planned to continue the tradition of multidisciplinary during the conference.

Key Points: 
  • Invited lectures, workshops, dedicated sessions for nursing, poster sessions and panel discussions are planned to continue the tradition of multidisciplinary during the conference.
  • This years program again promises to provide the right environment to foster learning and mutually beneficial interactions and collaborations.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.
  • The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Retrieved on: 
Tuesday, March 1, 2022
Annual report, Investment, Loss, PML, Government, Delinquent, Bank, FDIC, PCQ, Mission statement, Federal Reserve Board of Governors, News, PNF, Time, New, Unitary state, Risk, PMX, PMF, Government agency, Contingent convertible bond, Sale, NAV, Tax, Clos, Leg, Record, PZC, Income, PNI, PDO, PCK, Calendar, PIMCO, Environment, New York Stock Exchange, Life insurance, Security (finance), Fund

There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Key Points: 
  • There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.
  • The tax treatment and characterization of a Funds distributions may varysignificantly from time to time because of the varied nature of the Fundsinvestments.
  • As with any stock, the price of a Funds common shares will fluctuate with market conditions and other factors.
  • PIMCO Investments LLC, 1633 Broadway, New York, NY 10019, is a company of PIMCO.

Spectral Medical Reports Progress on Tigris Clinical Trial

Retrieved on: 
Friday, February 11, 2022
ICU, Patient, Toronto Stock Exchange, Bed, Mortality, Septic shock, CEO, Risk, COVID, RRT, SAMI, SOFA, Clinical trial, PMX, GLOBE, Health Canada, Standard of care, Federal Food, Drug, and Cosmetic Act, Lipopolysaccharide, MD, EDT, FDA, U.S. FDA, Knowledge, Research, News, Renal replacement therapy, TSX, UC, Sepsis, Randomized controlled trial, Pharmaceutical industry, Medical device, Spectral

TORONTO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.

Key Points: 
  • The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care.
  • Its gratifying to see the commitment from our participating Tigris sites, said Dr. John Kellum, Chief Medical Officer of Spectral.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.